Apelin-17 vs Elabela — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Apelin-17 is a 17-amino acid C-terminal fragment of the prepro-apelin precursor that binds and activates the APJ receptor (now APLNR) with the highest potency of all naturally occurring apelin isoforms. While apelin-13 is the best-characterized isoform, apelin-17 shows greater re...
Calculate Apelin-17 dose →Elabela (also called Apela or Toddler) is the second endogenous peptide ligand for the APJ receptor, discovered in 2013 independently through two approaches: as an essential zebrafish cardiac development factor (Toddler) and as a novel human APJ ligand (Elabela). Unlike apelin pe...
Calculate Elabela dose →| Parameter | Apelin-17 | Elabela |
|---|---|---|
| Category | Cardiovascular Peptide | Cardiovascular Peptide |
| Research | Preclinical / Phase I | Research |
| Half-Life | ~3-5 minutes IV (longer than apelin-13) | Short (minutes, estimated) |
| Typical Dose | 30-100 nmol/kg/min (IV infusion, clinical) | 5-500 nmol/kg (animal) |
| Frequency | Acute infusion protocols | Variable |
| Route | IV infusion (clinical studies); SC under investigation | Subcutaneous, Intravenous |
| FDA Status | Investigational (Phase I/II) | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.